The foundation:
News

Neuroimage: Clinical publishes latest article by Carla Abdelnour on dementia with Lewy bodies


The prestigious scientific journal Neuroimage: Clinical has just published online the article entitled “The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies”, whose main author is the neurologist and assistant director of the Clinical Trials Unit of Fundació ACE, Carla Abdelnour.

The article shows evidence of the possible combined effect of the proteins β-amyloid and tau in the brain atrophy suffered by people with dementia with Lewy bodies. Future research, using more automated methods and the inclusion of other biomarkers, should help to verify the location of these pathologies in the process of brain neurodegeneration that leads to this type of dementia, the study concludes.

The article published in Neuroimage: Clinical is the result of collaboration between Fundació ACE and the European Dementia with Lewy Bodies Consortium (E-DLB), of which Carla Abdelnour is a member of the steering committee. In addition, its content will form part of the doctoral thesis that Abdelnour is preparing at the Faculty of Medicine of the Autonomous University of Barcelona.

The main author of the study leads the research on dementia with Lewy bodies at Fundació ACE, in addition to being the coordinator of the FACESTARR project (Fundació ACE Research in Robotics and Social Technology). Recently, she has also been elected representative of the Executive Committee of the Area of Professional Interest on Clinical Trial Advances and Methods of the International Society for the Advancement of Alzheimer's Research and Treatment (ISTAART), which is part of the Alzheimer's Association. 
 

You might also like

Carla Abdelnour, internationally recognized in the field of clinical trials

27/04/2020Research
Carla Abdelnour, a neurologist at Fundació ACE, has been elected representative of the Executive Committee of the Area of Clinical Trials Advances and Methods of the International Society for the Advancement of Alzheimer's Research and Treatment (ISTAART)